Purpose and Appropriate Sample Types {#cytoa23725-sec-0001}
====================================

Here we present a 42 parameter panel to characterize myeloid immune cell subsets and T lymphocyte activation status in cryopreserved and barcoded single cell suspensions obtained from brain, spleen, and bone marrow of an orthotopic immunocompetent glioblastoma mouse model in a C57BL/6 background (Table [1](#cytoa23725-tbl-0001){ref-type="table"}). This panel is designed for mass cytometry by time of flight (CyTOF) and combines 34 antibodies against diverse cell surface and intracellular targets together with cisplatin for live/dead discrimination, iridium for cell identification, and six cellular barcodes [1](#cytoa23725-bib-0001){ref-type="ref"} to enable simultaneous multiplexed acquisition of up to 20 samples (Table [2](#cytoa23725-tbl-0002){ref-type="table"}). The panel is designed for a comprehensive evaluation of the immune system in different organs during murine in vivo studies in the field of glioblastoma immunology, but could also be applied to other disease models in the central nervous system (CNS) with possible systemic involvement, such as brain metastasis arising from other types of cancer, experimental autoimmune encephalomyelitis (EAE), or neurodegenerative disease models. Marker selection was partly based on a combination of previously reported panels studying CNS immune infiltrates [2](#cytoa23725-bib-0002){ref-type="ref"}, [3](#cytoa23725-bib-0003){ref-type="ref"}, [4](#cytoa23725-bib-0004){ref-type="ref"}, [5](#cytoa23725-bib-0005){ref-type="ref"}, [6](#cytoa23725-bib-0006){ref-type="ref"}, [7](#cytoa23725-bib-0007){ref-type="ref"}. The selected set of markers captures T lymphocytes (CD8+, CD4+, and regulatory T lymphocytes), dendritic cells (DC), monocytes, macrophages, microglia, tumor cells (when GFP positive), and granulocytes, and contains a set of antibodies to detect cell activation, migratory capacity and immune checkpoints (Table [2](#cytoa23725-tbl-0002){ref-type="table"}). The panel has been optimized with respect to marker selection, antibody clone usage, antibody‐metal pairing, and antibody concentration, and has room for additional markers by filling in a number of free channels as listed in Table [2](#cytoa23725-tbl-0002){ref-type="table"}.

###### 

Summary table for the application of this OMIP

  Purpose            Immunophenotyping of innate and adaptive immune cells in a murine glioblastoma model
  ------------------ --------------------------------------------------------------------------------------
  Species            Mouse
  Cell types         Single cells from Miltenyi neural tissue dissociation kit (P) treated brain
  Cross‐references   No similar OMIP

###### 

Summary table for the antibodies in this panel

  Target protein             Clone          Metal        Source        Purpose
  -------------------------- -------------- ------------ ------------- -----------------------------------------------------------
  Cell identification                                                  
  Barcodes                                  103--110Pd   Fluidigm      Staining standardization and doublet discrimination
  Iridium                                   191--193Ir   Fluidigm      Cell identification
  Cisplatin                                 194--195Pt   Fluidigm      Live/dead discrimination
  Cell classification                                                  
  CD45                       30‐F11         89Y          Fluidigm      All leukocytes
  CD3e                       145‐2C11       152Sm        Fluidigm      T lymphocytes
  TCRb                       H57‐597        169Tm        Fluidigm      T a/b lymphocyte receptor
  CD4                        RM4‐5          145Nd        Fluidigm      T helper lymphocytes
  Foxp3 (FJK16s)             FJK‐16s        158Gd        Fluidigm      Regulatory T lymphocytes
  CD8b                       536.7          168Er        Fluidigm      Cytotoxic T lymphocytes
  CD127 (IL‐7Ra)             A7R34          175Lu        Fluidigm      Memory T lymphocytes
  CD28                       37.51          151Eu        Fluidigm      T lymphocytes, natural killer cells
  Ly‐6G                      1A8            141Pr        Fluidigm      Granulocytes
  Ly‐6C                      HK1.4          150Nd        Fluidigm      Monocytes, macrophages
  CD11b (Mac‐1)              M1/70          148Nd        Fluidigm      Macrophages, microglia, dendritic cells, granulocytes
  CD11c                      N418           209Bi        Fluidigm      Dendritic cells
  CD14                       Sa14‐2         144Nd        Biolegend     Monocytes
  CD88                       20/70          161Dy        Biolegend     Monocytes, macrophages, neutrophils, eosinophils
  MHC class 2 I‐A/I‐E        M5/114.15.2    174Yb        Fluidigm      Antigen presenting cells, T lymphocyte activation?
  TMEM119                    106--6         146Nd        Abcam         Microglia
  CD49d                      R1‐2           176Yb        Biolegend     Exclusion marker for microglia
  CD169 (Siglec‐1)           3D6.112        142Nd        Biolegend     Dendritic cells, macrophages, microglia
  CD206 (Mannose receptor)   C068C2         160Gd        Biolegend     Macrophages, dendritic cells
  Siglec H                   440c           166Er        Genetex       Plasmacytoid dendritic cells, Microglia
  CD38                       90             153Eu        Biolegend     B lymphocyte (pre‐cursors), macrophages
  aGFP                       454,505        173Yb        Biolegend     Tumor cells
  Migration                                                            
  CCR2                       475,301        165Ho        RnD systems   Monocyte chemotaxis
  CCR6                       29‐2L17        156Gd        Fluidigm      Dendritic cell‐ and lymphocyte chemotaxis
  CD54 (ICAM‐1)              YN1/1.7.4      163Dy        Fluidigm      Leukocyte extravasation
  Activation                                                           
  Ly‐6A/E (Sca‐1)            D7             164Dy        Fluidigm      Hematopoietic stem cell marker/ activation of lymphocytes
  Ki‐67                      B56            172Yb        Fluidigm      Cell proliferation
  CD69                       H1.2F3         143Nd        Fluidigm      Activated T lymphocytes
  CD44                       IM7            171Yb        Fluidigm      Activated lymphocytes
  CD150 (SLAM, IPO‐3)        TC15‐12F12.2   167Er        Fluidigm      Activated lymphocytes and dendritic cells
  Immune checkpoints                                                   
  CD152 (CTLA‐4)             UC10‐4B9       154Sm        Fluidigm      Co‐inhibitory molecule
  CD279 (PD‐1)               J43            159Tb        Fluidigm      Co‐inhibitory molecule
  CD274 (PD‐L1)              10F.9G2        155Gd        Biolegend     PD1 ligand
  CD366 (Tim‐3)              RMT3‐23        162Dy        Fluidigm      Co‐inhibitory molecule
  Free channels                                                        
                                            113--115In                 
                                            147Sm                      
                                            149Sm                      
                                            170Er                      

Background {#cytoa23725-sec-0002}
==========

In the last decades enormous efforts have been made to develop therapeutic interventions that boost antitumor immunity, including adoptive cell transfer, anti‐cancer vaccination, application of oncolytic viruses, and immune checkpoint inhibition [8](#cytoa23725-bib-0008){ref-type="ref"}, [9](#cytoa23725-bib-0009){ref-type="ref"}. A wide range of immunotherapeutic strategies are being tested in glioblastoma, advanced by successes in other tumor types. In these approaches particularly T cells are targeted as final effector cells by, for example, dendritic cell vaccination or immune checkpoint inhibition, but durable responses remain limited to case reports [10](#cytoa23725-bib-0010){ref-type="ref"}. Boosted T cell responses as a result of, for example, vaccination strategies encounter functional impairment due to immune inhibitory mechanisms both in the tumor microenvironment and systemically. To overcome T cell inhibition hope was pinned on immune checkpoint inhibition with monoclonal antibody therapy against PD1 and CTLA‐4. Nevertheless, to date clinical trials testing immune checkpoint inhibition in glioblastoma have not shown impressive results [11](#cytoa23725-bib-0011){ref-type="ref"}. Clearly glioblastoma‐specific immune suppression is a complex and unsolved problem that remains an obstacle for successful immunotherapies. Therefore, a better understanding of glioblastoma immune escape and contributing factors is warranted, alongside the development of biomarkers for patient selection and prediction of clinical response. Immune suppression in glioblastoma is largely mediated by infiltration of monocytes into the glioblastoma microenvironment [12](#cytoa23725-bib-0012){ref-type="ref"}. Myeloid immune cells dominate immune infiltrates and are involved in glioblastoma disease progression [13](#cytoa23725-bib-0013){ref-type="ref"}, [14](#cytoa23725-bib-0014){ref-type="ref"}, [15](#cytoa23725-bib-0015){ref-type="ref"}. Although some subsets have been studied in isolation, the different types of infiltrating myeloid and lymphoid cells, their recruitment from the bone marrow and spleen, and their phenotypic distribution need further investigation.

Mass cytometry provides for the simultaneous measurement of more than 40 parameters at single cell resolution, improving the ability of cytometry to characterize the complexity of the immune system [16](#cytoa23725-bib-0016){ref-type="ref"}. Similar to the development of antibody panels for multichromatic fluorescence cytometry, mass cytometry panel development requires optimization of antibody‐metal pairing, conjugation of antibodies with metal polymers, determination of optimal antibody concentrations, and optimization of buffers and staining conditions. Here we developed a mass cytometry immunophenotyping panel, which was designed to quantify population frequencies and to infer functional states of T cells, including activation, differentiation, exhaustion, or anergy in the murine glioblastoma microenvironment (Fig. [1](#cytoa23725-fig-0001){ref-type="fig"}) and spleen. Furthermore, our panel helps to differentiate and quantify a multitude of glioblastoma infiltrating and bone marrow derived myeloid cell subsets and immune cells resident to the bone marrow. Although this panel is optimized for single cell suspensions obtained from mouse brain, spleen, and bone marrow it could also be applied to the study of innate and adaptive components of the immune system in other mouse organs. Single cell suspensions were generated using mechanical dissociation and enzymatic digestion using the Neural Tissue Dissociation kit P (Miltenyi, Germany) [17](#cytoa23725-bib-0017){ref-type="ref"}. After live/dead staining and barcoding [1](#cytoa23725-bib-0001){ref-type="ref"} cells were cryopreserved until antibody staining and mass cytometry analysis (Fig. [1](#cytoa23725-fig-0001){ref-type="fig"}A). Following data pre‐processing including bead normalization [18](#cytoa23725-bib-0018){ref-type="ref"} and debarcoding [1](#cytoa23725-bib-0001){ref-type="ref"}, the first gates aimed at exclusion of normalization beads, cell debris, doublets, and dead cells (^140^Ce^−^, ^193^Ir^+^, and ^194^Pt^−^). Next, we plotted CD45 against CD11c to identify CD45^hi^CD11c^hi^ DCs (population 1). Plotting CD45 against CD11b for non‐DCs resulted in four main populations: CD45^−^ non‐immune cells (population 2), CD45^+^CD11b^−^ lymphocytes, CD45^+^CD11b^+^ infiltrating myeloid cells, and CD45^dim^CD11b^+^ microglia. CD45^−^ cells include tumor cells and non‐immune non‐tumor brain resident cells, such as glial cells or neurons. In the CD45^+^CD11b^−^CD3^+^TCRb^+^ cells we identified CD8^+^ T cells, CD4^+^ T cells, and CD4^+^FoxP3^+^ regulatory T cells (populations 3, 4, and 5, respectively). Next, we identified microglia as being the CD44^−^CD49d^−^ cells in the CD11b^+^CD45^dim^ population (population 6). Based on MHC‐II, CCR2, and PD‐L1 expression we identified three clusters of microglia with different activation states (6A, 6B, 6C). CD45^+^CD11b^+^ infiltrating myeloid cells contain granulocytes (population 7), Ly6C^hi^CCR2^hi^ recently extravasated monocytes (population 8), and some clusters of macrophages with different phenotypes and/or states of activation (9A, 9B, 9C, 9D, 9E, and 9F) based on their expression of CCR2, MHC‐II, PD‐L1, CD38, and CD88. Gated populations were identified based on two‐dimensional embeddings of the high dimensional space visualized using the viSNE algorithm in Cytobank (Fig. [1](#cytoa23725-fig-0001){ref-type="fig"}B,C).

![Identification of main leukocyte populations and CD45^−^ cells in murine glioblastoma by manual gating and representation by viSNE. (**A**) Example gating of cell subsets. (**B**) viSNE embeddings color‐coded for lineage markers. (**C**) Populations gated in A are color‐coded according to the legend inset and displayed in the viSNE map. (**D**) Heatmap describing relative expression of lineage markers across the populations described in A, B, and C. (**E**) Heatmap displaying median mass intensity (ArcSinH(5)‐transformed) of activation and migration markers across the populations described in A, B, and C.](CYTO-95-422-g001){#cytoa23725-fig-0001}

Enzymatic digestions often result in the cleavage of molecules on the membrane of immune cells, which could have detrimental effect in their recognition by antibodies. In order to allow direct comparison amongst different organs (brain, spleen, and bone marrow) all samples were subjected to the same enzymatic treatment as it was required for the processing of the brain samples. The panel presented in this OMIP has been optimized to the single cell suspension preparation procedure as suggested by the manufacturer with some minor adjustments (see Supporting Information "Online Protocol"). Care should be taken to specifically address any effects of alterations in the tissue dissociation protocol to the performance of this panel.

Similarity to Other OMIPs {#cytoa23725-sec-0003}
=========================

This OMIP is partly overlapping with OMIP‐032, which describes two murine multicolor immunofluorescence panels including the following markers to detect B and T lymphocytes, natural killer cells, dendritic cells, macrophages, monocytes, and neutrophils: CD45, TCRβ, CD4, CD8, Ly6C, CD49b, Ly6G, CD11c, MHCII, CD206, NKp46, CD62L, and CD44 [19](#cytoa23725-bib-0019){ref-type="ref"}. These markers overlap with our panel except for CD49b, NKp46, and CD62L. Since our panel is more focused on activation and exhaustion in T lymphocytes, we included more antibodies against activation markers and co‐inhibitory molecules (immune checkpoints) rather than the presence of naïve or memory T cells. Also OMIP‐031 has overlap with a panel aimed at immune checkpoint expression [20](#cytoa23725-bib-0020){ref-type="ref"}, which reports the following markers: CD3, CD4, CD8, CD69, CD44, CD45RA, CD27, CD62L, KLRG127, CD127, PD‐1, CTLA4, TIM‐3, LAG‐3, and CD45. Our panel includes all of these markers except for CD45RA, CD27, CD62L, KLG127, and LAG‐3. Previously, three other mass cytometry panels have been published. They focus on the characterization of human peripheral leukocytes (OMIP‐34), human head and neck cancer (OMIP‐45), and the quantification of calcium sensors and channels in lymphocyte subsets [21](#cytoa23725-bib-0021){ref-type="ref"}, [22](#cytoa23725-bib-0022){ref-type="ref"}, [23](#cytoa23725-bib-0023){ref-type="ref"}. This is the first mass cytometry OMIP for a comprehensive characterization of the mouse immune system. All data used generated during the optimization and verification of this panel can be found in FlowRepository under ID: FR‐FCM‐ZYUF.
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**Appendix S1** Supporting Information.

###### 

Click here for additional data file.
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